Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer

Completed

Conditions studied: Breast Cancer

In brief

This study examines the relationship among epigenetic alterations and the development and persistence of psychoneurologic symptoms (cognitive dysfunction, depressive symptoms, anxiety, fatigue, sleep disturbance, and pain) in women receiving chemotherapy for early stage breast cancer. The relationship among inflammatory markers and psychoneurologic symptoms will also be explored. It is hypothesized: 1. Chemotherapy triggers inflammatory activation, which in turn leads to the acquisition of genetic alterations. These alterations result in cellular changes and are modified over time. 2. Inflammatory activation and epigenetic alterations are related to the temporal development, severity, and persistence of psychoneurologic symptoms.

Key facts

Study ID

NCT01411943

Run by

Virginia Commonwealth University

People needed

75

Starts

2011-01-01

Expected to finish

2015-07-01

Last updated by the study team

2015-12-08

Who can join

Age: 21 and older, up to 81. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• At least 21 years of age
• Diagnosed with stage I to IIIa Breast Cancer
• Scheduled to receive chemotherapy

You may not qualify if…

• previous cancer history
• previous chemotherapy history
• dementia
• active psychosis

Where it is running

• Peninsula Cancer Institute — Newport News, Virginia, United States
• Virginia Commonwealth University — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.